Are any peptides FDA approved for weight loss?

Yes. Semaglutide and tirzepatide are FDA-approved peptide drugs with approvals that include chronic weight management, supported by large randomised trials. That is the position as of September 2026.

Is compounded semaglutide the same as the approved product?

No. Compounded product is not an FDA-approved formulation, and its purity, concentration and stability depend entirely on the pharmacy. FDA has issued repeated warnings about compounded GLP-1 preparations.

What is MOTS-c researched for?

MOTS-c is a mitochondrial-derived peptide studied in animals for insulin sensitivity and metabolic regulation. It has no controlled human outcome data, and in July 2026 FDA proposed not to list it for compounding.

§ — Researched for · Metabolic health & weight

Peptides researched for metabolic health & weight

Peptide therapy for metabolic health is the one area where approved, well-studied drugs exist: semaglutide and tirzepatide are FDA-approved GLP-1-class peptides with large randomized trials behind them. Research-stage peptides such as MOTS-c and tesamorelin sit far behind that evidence.

Approved drug with randomized controlled trials for the approved indication

Human clinical data exists, but no approval for the researched use

Animal or in-vitro data only, no controlled human trials

No published clinical data; use rests on anecdote

Reviewed September 2026 · Sources: FDA, EMA

02 — What is being studied

The research field, in plain terms.

Two research lines run in parallel here. The first is incretin pharmacology: GLP-1 and dual GLP-1/GIP receptor agonists, studied in multi-year randomised trials with body weight, HbA1c and cardiovascular events as endpoints. This is the most heavily documented peptide field in medicine, and the approvals rest on that documentation rather than on mechanism.

The second line is mitochondrial and pituitary signalling — mitochondrial-derived peptides such as MOTS-c, and growth-hormone-releasing analogues such as tesamorelin, where the endpoints under study are visceral fat, insulin sensitivity and lipid handling. Tesamorelin holds a narrow approval in HIV-associated lipodystrophy; MOTS-c has no controlled human outcome data at all. The gap between the incretin evidence and everything else in this group is wide, and treating the two as one category is the most common error in marketing as of September 2026.

03 — The table

Every peptide in this group, with its status.

Peptide	Researched for	Evidence	Regulatory status	As of
Semaglutide	Type 2 diabetes, obesity, cardiovascular outcomes, NASH, kidney outcomes, alcohol use, Alzheimer's disease.	A	FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk reduction in adults with obesity. Compounded versions are permitted only during declared shortages; shortage status must be verified.	2026-09-06
Tesamorelin	Visceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.	A	FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Use for any other purpose is off-label.	2026-09-06
Tirzepatide	Obesity, type 2 diabetes, sleep apnea, heart failure with preserved ejection fraction, cardiovascular outcomes.	A	FDA-approved for type 2 diabetes (Mounjaro), chronic weight management and obstructive sleep apnea in obesity (Zepbound). Compounding permitted only during declared shortages; shortage status must be verified.	2026-09-06
MOTS-c	Insulin sensitivity, exercise capacity, metabolic regulation, aging biology.	C	Not FDA-approved. Reviewed by PCAC on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Not eligible for compounding.	2026-09-06

04 — Per peptide

Status first, then research.

Semaglutide

Regulatory status · United States · as of September 2026

FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk reduction in adults with obesity. Compounded versions are permitted only during declared shortages; shortage status must be verified.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forType 2 diabetes, obesity, cardiovascular outcomes, NASH, kidney outcomes, alcohol use, Alzheimer's disease.

Full profile: Semaglutide →

Tesamorelin

Regulatory status · United States · as of September 2026

FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Use for any other purpose is off-label.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forVisceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.

Full profile: Tesamorelin →

Tirzepatide

Regulatory status · United States · as of September 2026

FDA-approved for type 2 diabetes (Mounjaro), chronic weight management and obstructive sleep apnea in obesity (Zepbound). Compounding permitted only during declared shortages; shortage status must be verified.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forObesity, type 2 diabetes, sleep apnea, heart failure with preserved ejection fraction, cardiovascular outcomes.

Full profile: Tirzepatide →

MOTS-c

Regulatory status · United States · as of September 2026

Not FDA-approved. Reviewed by PCAC on July 23, 2026; FDA proposed not to add it to the 503A Bulks List. Not eligible for compounding.

Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026

Researched forInsulin sensitivity, exercise capacity, metabolic regulation, aging biology.

Full profile: MOTS-c →

05 — What the data does not show

The limits of this group.

Benefit in normal-weight adults, preservation of lean mass without resistance training, and the safety of unregulated compounded product have not been shown.

06 — Questions for your physician

Six questions worth printing.

01What is your primary board certification, and in what year did you obtain it?
02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
03Which human trials support this use, and what were their size and duration?
04Where does the product come from, and can you show me a certificate of analysis for this batch?
05What outcome will we measure, when, and what happens if it does not improve?
06What is the total cost for the first three months, in writing?

Providers in the registry offering peptide therapy

Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.

Longevity network

Longevity Centers of America (Netzwerk)

Hormone therapy (HRT / BHRT)
Peptide therapy

ListedView profile →

Age-management practice

Micah Olson, MD - Age Management Biltmore

Phoenix, AZ

VO2max testing
Hormone therapy (HRT / BHRT)
Peptide therapy
DEXA body composition

ListedView profile →

Reviewed September 2026 · Sources: FDA, EMA

This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.